A clinical trial carried out by Thomas et al. [164] included 29 patients (Phase I = n:9; Phase II = n:20) with glioblastoma who underwent radiation therapy followed by intravenous treatment with the CXCR4 inhibitor plerixafor. The gene discussed is CXCR4; the disease is glioblastoma.